91.42
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché ALC Giù?
Forum
Previsione
Storia dei dividendi
Precedente Chiudi:
$90.58
Aprire:
$91.87
Volume 24 ore:
2.08M
Relative Volume:
1.28
Capitalizzazione di mercato:
$45.22B
Reddito:
$9.91B
Utile/perdita netta:
$1.02B
Rapporto P/E:
44.60
EPS:
2.05
Flusso di cassa netto:
$665.00M
1 W Prestazione:
+10.30%
1M Prestazione:
+2.77%
6M Prestazione:
-5.37%
1 anno Prestazione:
+12.74%
Alcon Inc Stock (ALC) Company Profile
Nome
Alcon Inc
Settore
Industria
Telefono
-
Indirizzo
-
Confronta ALC con altri titoli
Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
---|---|---|---|---|---|---|
![]()
ALC
Alcon Inc
|
91.42 | 45.22B | 9.91B | 1.02B | 665.00M | 2.05 |
![]()
ISRG
Intuitive Surgical Inc
|
488.27 | 174.93B | 8.35B | 2.32B | 1.30B | 6.41 |
![]()
BDX
Becton Dickinson Co
|
202.04 | 58.01B | 20.64B | 1.73B | 2.94B | 6.02 |
![]()
RMD
Resmed Inc
|
213.97 | 31.43B | 4.93B | 1.25B | 1.38B | 8.47 |
![]()
COO
The Cooper Companies, Inc.
|
77.80 | 15.49B | 3.90B | 392.30M | 288.10M | 1.95 |
Alcon Inc Stock (ALC) Upgrades & Downgrades
Data | Azione | Analista | Modifica della valutazione |
---|---|---|---|
2025-03-28 | Reiterato | Needham | Buy |
2025-03-25 | Aggiornamento | BofA Securities | Neutral → Buy |
2025-01-24 | Reiterato | Needham | Buy |
2025-01-10 | Aggiornamento | Redburn Atlantic | Neutral → Buy |
2024-12-17 | Reiterato | Needham | Buy |
2024-11-12 | Reiterato | Needham | Buy |
2024-10-10 | Aggiornamento | Redburn Atlantic | Sell → Neutral |
2024-09-10 | Aggiornamento | RBC Capital Mkts | Sector Perform → Outperform |
2024-07-15 | Aggiornamento | Morgan Stanley | Underweight → Equal-Weight |
2024-05-15 | Aggiornamento | Oppenheimer | Perform → Outperform |
2024-04-10 | Iniziato | Goldman | Buy |
2024-03-14 | Iniziato | RBC Capital Mkts | Sector Perform |
2024-02-06 | Ripresa | KeyBanc Capital Markets | Overweight |
2024-01-23 | Iniziato | Bernstein | Outperform |
2023-12-18 | Downgrade | Redburn Atlantic | Neutral → Sell |
2023-12-12 | Iniziato | Stifel | Buy |
2023-12-04 | Downgrade | Morgan Stanley | Equal-Weight → Underweight |
2023-08-17 | Aggiornamento | JP Morgan | Neutral → Overweight |
2023-05-30 | Ripresa | Morgan Stanley | Equal-Weight |
2023-05-10 | Aggiornamento | Robert W. Baird | Neutral → Outperform |
2023-03-01 | Aggiornamento | Societe Generale | Sell → Hold |
2022-12-22 | Iniziato | Mizuho | Buy |
2022-11-17 | Downgrade | Societe Generale | Hold → Sell |
2022-08-11 | Downgrade | Societe Generale | Buy → Hold |
2022-05-13 | Ripresa | Credit Suisse | Outperform |
2022-05-12 | Aggiornamento | Stephens | Equal-Weight → Overweight |
2022-04-08 | Iniziato | Needham | Buy |
2022-03-11 | Iniziato | BofA Securities | Buy |
2022-01-18 | Downgrade | Stephens | Overweight → Equal-Weight |
2022-01-07 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
2021-10-01 | Iniziato | Oppenheimer | Perform |
2021-07-14 | Iniziato | Deutsche Bank | Buy |
2021-05-06 | Aggiornamento | Citigroup | Sell → Neutral |
2021-03-22 | Aggiornamento | BTIG Research | Neutral → Buy |
2020-11-12 | Downgrade | Guggenheim | Buy → Neutral |
2020-07-06 | Downgrade | Citigroup | Neutral → Sell |
2020-07-06 | Iniziato | KeyBanc Capital Markets | Sector Weight |
2020-06-16 | Aggiornamento | Guggenheim | Neutral → Buy |
2020-04-08 | Downgrade | Robert W. Baird | Outperform → Neutral |
2020-03-26 | Aggiornamento | Argus | Hold → Buy |
2020-03-24 | Aggiornamento | Societe Generale | Sell → Hold |
2020-03-13 | Aggiornamento | UBS | Neutral → Buy |
2020-03-05 | Iniziato | Citigroup | Neutral |
2020-02-26 | Aggiornamento | Berenberg | Hold → Buy |
2020-01-08 | Iniziato | Argus | Hold |
2019-10-29 | Iniziato | Stephens | Equal-Weight |
2019-08-21 | Reiterato | BofA/Merrill | Neutral |
2019-06-24 | Iniziato | SVB Leerink | Mkt Perform |
2019-06-14 | Iniziato | BTIG Research | Neutral |
2019-05-10 | Iniziato | Robert W. Baird | Outperform |
2019-05-02 | Iniziato | Credit Suisse | Outperform |
Mostra tutto
Alcon Inc Borsa (ALC) Ultime notizie
Aniridia Treatment Market Is Going to Boom | Major Giants Alcon, Santen Pharmaceutical, Johnson & Johnson Vision - openPR.com
There's Been No Shortage Of Growth Recently For Alcon's (VTX:ALC) Returns On Capital - Yahoo Finance
Alcon lines up product launches in India, bets on rising demand for advanced eye care - MSN
Alcon: A Clear Vision, But Fully Valued (NYSE:ALC) - Seeking Alpha
GE HealthCare Hires Alcon Exec Jeannette Bankes as Patient Care Solutions CEO - Medical Product Outsourcing
Ophthalmic Devices Market Set to Attain Valuation of US$ 83.33 Billion By 2033 | Astute Analytica - GlobeNewswire Inc.
Here’s Why ClearBridge Large Cap Growth Strategy Sold Alcon (ALC) - Insider Monkey
Tesla, Warner Bros fend off some claims in 'Blade Runner 2049' ad dispute - Reuters
Alcon (VTX:ALC) Seems To Use Debt Quite Sensibly - simplywall.st
Alcon Scoops Up Aurion Biotech With Intent of Advancing Ophthalmology Cell Therapy AURN001 - CGTLive®
Bernstein raises Alcon stock price target to CHF99 from CHF97.50 - Investing.com Canada
Alcon, Aurion Reach Accord in Dispute Over Public Offering - Bloomberg Law News
Bernstein raises Alcon stock price target to CHF99 from CHF97.50 By Investing.com - Investing.com South Africa
Dr. Jeffrey Martin of SightMD Becomes One of the First on Long Island to Implant the new Clareon® PanOptix® Pro Lens by Alcon - PRWeb
Alcon Publishes Agenda for 2025 Annual General Meeting - Business Wire
ALC Stock May Rise With the Introduction of PanOptix Pro in US - MSN
Alcon Introduces Clareon PanOptix Pro Intraocular Lens - Medical Product Outsourcing
Alcon Expands Leadership in IOL Innovation with Clareon PanOptix - GuruFocus
Alcon Expands Leadership in IOL Innovation with Clareon PanOptix Pro, Delivering Best-in-Class Light Utilization and Less Light Scatter - Business Wire
The Zacks Analyst Blog Highlights Alcon, Glaukos and Regeneron Pharmaceuticals - Yahoo Finance
Dry Eye Disease Market Growth in Future Scope 2025-2032 | - openPR.com
KeyBanc raises Alcon stock price target to $112 on growth outlook - Investing.com Canada
KeyBanc raises Alcon stock price target to $112 on growth outlook By Investing.com - Investing.com South Africa
3 Stocks to Watch in the Evolving Cell-Based Ophthalmic Therapy Space - TradingView
Deutsche Bank lifts Alcon stock price target to CHF96 from CHF92 - Investing.com Canada
Deutsche Bank lifts Alcon stock price target to CHF96 from CHF92 By Investing.com - Investing.com South Africa
Alcon Stock Might Rise as Clareon Vivity IOL Secures CE Mark Approval - MSN
Stifel maintains Alcon stock Buy rating, $100 target By Investing.com - Investing.com Australia
Citi maintains Alcon stock Buy rating, CHF99.00 target By Investing.com - Investing.com South Africa
Mizuho lifts Alcon stock price target to $120, maintains Outperform By Investing.com - Investing.com Canada
Taxation With Representation: Norton Rose, Latham, Ashurst - Law360
Oppenheimer Remains a Buy on Alcon (ALC) - The Globe and Mail
Stifel maintains Alcon stock Buy rating, $100 target - Investing.com
Alcon stock price target raised to $110 at Needham - Investing.com India
Alcon stock price target raised to $110 at Needham By Investing.com - Investing.com Australia
Alcon (ALC) Soars 6.0%: Is Further Upside Left in the Stock? - Yahoo Finance
Mizuho lifts Alcon stock price target to $120, maintains Outperform - Investing.com
Jefferies raises Alcon stock price target to $115, maintains Buy - Investing.com India
Jefferies raises Alcon stock price target to $115, maintains Buy By Investing.com - Investing.com South Africa
Citi maintains Alcon stock Buy rating, CHF99.00 target - Investing.com India
Alcon (VTX:ALC) ascends 4.7% this week, taking five-year gains to 80% - Yahoo Finance
Alcon Acquires Majority Interest in Aurion Biotech, Inc. to Advance Cell Therapy for Corneal Endothelial Disease - VisionMonday.com
Alcon Inc’s Acquisition of LENSAR Inc - Global Legal Chronicle
Alcon: Innovation, Commercial Excellence, and Robust Momentum Mark Successful Capital Markets Day - Morningstar
Alcon's Future Looks Fruitful as New Innovation and Commercial Execution Spark Market Outperformance - Morningstar
All eyes on ophthalmic cell therapy space as Alcon takes majority stake in Aurion - FirstWord Pharma
Alcon Inc Azioni (ALC) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):